Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, 4-Week, Randomised, Multi-Centre, Phase IV Study to Compare the Efficacy and Safety of Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder

NCT00672490 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00672490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00672490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, 4-Week, Randomised, Multi-Centre, Phase IV Study to Compare the Efficacy and Safety of Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2008
Completion date
July 31, 2009
Enrollment
376 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acute mania in bipolar disorder